Incorporation of an Asp-Ser sequence to form an RGDS-like motif in hirutonin: The effect on in vitro platelet function

Thrombosis Research

Volumn 99, Issue 4, 2000, Pages 343-352

  Van Wyk, Veronica ^a   Leblond, Lorraine ^b   Winocour, Peter D ^b   Devine, Dana V ^c,d   Gyongyossy Issa, Maria I C ^c,d  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

^b BioChem Pharma   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d CANADIAN BLOOD SERVICES   (Canada)

Author keywords

Antithrombins; Peptides; Platelet aggregation

Indexed keywords

CHIMERIC PROTEIN; HIRUTONIN; PADGEM PROTEIN; PSEUDOPEPTIDE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; HEMOSTASIS; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADENOSINE TRIPHOSPHATE; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; BLOOD COAGULATION TESTS; FIBRINOGEN; FIBRINOLYTIC AGENTS; HEMOSTASIS; HIRUDINS; HUMANS; OLIGOPEPTIDES; PEPTIDES; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN BINDING; PROTEIN ENGINEERING; VON WILLEBRAND FACTOR;

EID: 0034663202     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00257-7     Document Type: Article

References (28)

1. Markwardt F. Hirudin as an inhibitor of thrombin. Meth Enzym. 19:1970;924-932.
2. Harmon J.T., Jamieson G.A. Activation of platelets by alpha thrombin is a receptor mediated event. D-Phenyl-L-alanyl-L-prolyl-argenine chloromethyl ketone-thrombin, but not N-alphatosyl-L-lysine chloromethyl ketone-thrombin, binds to the high affinity thrombin receptor. J Biol Chem. 261:1988;15928-15933.
3. Maraganore J.M., Bourdon P., Jablonski J., Ramachandran K.L., Fenton J.W. II Design and characterization of hirulogs. A novel class of bivalent peptide inhibitors of thrombin Biochemistry. 29:1990;7095-7101.
4. Cappiello M., Vilardo P.G., Del Corso A., Mura U. Hirunorms, novel hirudin-like direct thrombin inhibitors. Gen Pharmac. 30(4):1998;565-568.
5. Maraganore J.M., Chao B., Joseph M.L., Jablonski J., Ramachandran K.L. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem. 264:1989;8692-8698.
6. DiMaio J., Gibbs B., Lefebvre J., Konishi Y., Munn D., Yue S.Y. Synthesis of a homologous series of ketomethylene arginyl pseudopeptides and application to low molecular weight hirudin-like thrombin inhibitors. J Med Chem. 5:1992;3331-3341.
7. Ruggeri Z.M., Houghten R.A., Russell S.R., Zimmerman T.S. Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets. Proc Natl Acad Sci USA. 83:1986;5708-5712.
8. Taylor D.B., Gartner T.K. A peptide corresponding to GPIIbα300-12, a presumptive fibrinogen γ-chain binding site on the platelet integrin GPIIb/IIIa, inhibits the adhesion of platelets to at least four adhesive ligands. J Biol Chem. 267:1992;11729-11733.
9. Cook N.S., Kottirsch G., Zerwes H.-G. Platelet glycoprotein IIb/IIIa antagonists. Drugs of the Future. 19:1994;135-159.
10. Coller B.S., Scudder L.E., Beer J., Gold H.K., Folts J.D., Cavagnaro J., Jordan R., Wagner C., Iuliucci J., Knight D., Ghrayeb J., Smith G., Weisman H.F., Berger H. Monoclonal antibodies to platelet GPIIb/IIIa as antithrombotic agents. Annals NJ Acad Sciences. 614:1991;193-213.
11. Tcheng J.E., Harrington R.A., Kottke-Marchant K., Kleinman N.S., Ellis S.G., Kereiakes D.J., Mick M.J., Navetta F.L., Smith J.E., Worley S.J. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integringlycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation. 91:1995;2151-2157.
12. Peerlinck K., De Lepeleire I., Goldberg M., Farrell D., Barrett J., Hand E., Panebianco D., Deckmyn H., Vermylen J., Arnout J. MK-383 (L-700,462), a selective non-peptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation. 88:1993;1512-1517.
13. Knapp A., Degenhardt T., Dodt J. Hirudisins. Hirudin-derived thrombin inhibitors with disintegrin activity. J Biol Chem. 267(34):1994;24230-24234.
14. Church F.C., Phillips J.E., Woods J.L. Chimeric antithrombin peptide. Characterization of an Arg-Gly-Asp (RGD)- and hirudin carboxyl terminus-containing synthetic peptide J Biol Chem. 266(18):1991;11975-11979.
15. Leblond L., DiMaio J., Winocour P.D. Insertion of the Asp-Ser sequence in the p' position of hirutonin provides molecules having both antithrombin and disintegrin activity. Thromb Res. 93(4):1999;171-181.
16. Van Zyl W.B., Pretorius G.H.J., Hartmann M., Kotzé H.F. Production of a recombinant antithrombotic and fibrinolytic protein, PLATSAK, in Escherichia coli. Thromb Res. 88:1997;419-426.
17. DiMaio J., Ni F., Gibbs B., Konishi Y. A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond. FEBS Letter. 282:1991;47-52.
18. Van Wyk V., Heyns AduP Low molecular weight heparin as an anticoagulant for in vitro platelet function studies. Thromb Res. 57:1990;601-609.
19. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 90:1999;1631-1632.
20. Kotzé H.F., Badenhorst P.N., Lamprecht S., Meiting M., Van wyk V., Nuyts K., Stassen J.M., Vermylen J., Deckmyn H. Prolonged inhibition of acute arterial thrombosis and high dosing of a monoclonal anti-platelet glycoprotein Iib/IIIa antibody in a baboon model. Thromb Haemost. 74(2):1995;751-757.
21. Yamashita T., Tsuda Y., Konishi Y., Okada Y., Matsuoka A., Giddings J.C., Yamamoto J. The antithrombotic effect of potent bifunctional thrombin inhibitors based on hirudin sequence P551 and P532, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb Res. 90:1998;199-206.
22. Van Wyk V., Neethling W.M., Badenhorst P.N., Kotzé H.F. R-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons. J Cardiovasc Surg. 39:1998;633-639.
23. Kasirer-Friede A., Legrand C., Frojmovic M.M. Thrombin receptor occupancy modulates aggregation efficiency and platelet surface expression of vWf and thrombospondin at low thrombin concentrations. Thromb Haemostas. 81:1999;967-975.
24. Hayes K.L., Tracy P.B. The platelet high affinity binding site for thrombin mimics hirudin, modulates thrombin-induced platelet activation, and is distinct from the glycoprotein Ib-V-IX complex. J Biol Chem. 274:1999;972-980.
25. Katagiri Y., Hayashi Y., Yamatomo K., Tanoue K., Kosaki G., Yamazaki H. Localization of von Willebrand factor and thrombin-interactive domains on human platelet glycoprotein Ib. Thromb Haemostas. 63:1990;122-126.
26. Alevriadou R.B., Moake J.L., Turner N.A., Ruggeri Z.M., Folie B.J., Philips M.D., Schreiber A.B., Hrinda M.E., McIntire L.V. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood. 81:1993;1263-1276.
27. Falati S., Edmead C.E., Poole A.W. Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor γ chain, Fyn, and Lyn to activate human platelets. Blood. 94:1999;1648-1656.
28. Goto S., Eto K., Ikeda Y., Handa S. Abiximab not RGD peptide inhibits von Willebrand factor-dependent platelet activation under shear. Lancet. 353:1999;809-811.